A Retrospective Observational Study of Hypoxic COVID-19 Patients Treated with Immunomodulatory Drugs in a Tertiary Care Hospital
Bharat Purandare, Prasad Rajhans, Sameer Jog, Parikshit Prayag, Harshwardhan S Pawar, Vikram L Narasimhan, Gauri Oak, Amruta Bedekar, Prasad Akole, Shailaja Chavan, Vishnu Telbhare, Dnyaneshwar Diwane, Manasi Shahane, Amrita Prayag, Shreyas Bhor
Indian Journal of Critical Care Medicine, doi:10.5005/jp-journals-10071-23599
Objectives: To describe the demographics and evaluate the clinical outcomes of hypoxic coronavirus disease-2019 (COVID-19) patients treated with different immunomodulatory (IM) drugs in a resource-limited setting.
Materials and methods: We conducted a retrospective cohort study of these patients admitted to our hospital between March 22 and May 31, 2020. Data were abstracted from multiple electronic data sources or patient charts to provide information on patient characteristics, clinical, laboratory variables, and outcomes. Results: A total of 134 patients met the inclusion criteria and were followed up till June 7, 2020. The median age of the patients was 55.6 years (range 20-89 years) and 68% were men. At least one comorbidity was seen in 72% of the patients with diabetes (44%) and hypertension (46%) being the most common. At triage, fever (82%), shortness of breath (77%), and cough (61%) were the most common presenting symptoms. A PaO 2 /FiO 2 ratio less than 300 was seen in 60%, and 4.5% required invasive mechanical ventilation within 72 hours of hospital admission. Five immunomodulatory agents (hydroxychloroquine, methylprednisolone, colchicine, etoricoxib, and tocilizumab) were administered in different combinations. Overall, in-hospital mortality was 26.9%, and 32% required mechanical ventilation. Around 69% of patients were discharged home. Five variables (SpO 2 , PaO 2 /FiO 2 ratio, leukocytosis, lymphopenia, and creatinine) on admission were found to be significant in the patients who died.
Conclusion: Our study provides the characteristics and outcomes of hypoxic COVID-19 patients treated with IM drugs in varied combination. Five independent variables were strong predictors of mortality.
References
Alijotas-Reig, Esteve-Valverde, Belizna, Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: a comprehensive review, Autoimmun Rev,
doi:10.1016/j.autrev.2020.102569Andrews, Areekal, Rajesh, Krishnan, Suryakala et al., First confirmed case of COVID-19 infection in India: a case report, Indian J Med Res,
doi:10.4103/ijmr.IJMR_2131_20Borba, Val, Sampaio, Alexandre, Melo et al., Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, JAMA Network Open,
doi:10.1001/jamanetworkopen.2020.8857Chorin, Dai, Shulman, Wadhwani, Bar-Cohen et al., The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin, Nat Med,
doi:10.1038/s41591-020-0888-2Cruz, Ruiz-Antorán, Gómez, López, Sánchez et al., Impact of glucocorticoid treatment in SARS-CoV-2 infection mortality: a retrospective controlled cohort study, Antimicrob Agents Chemother,
doi:10.1128/aac.01168-20Deftereos, Giannopoulos, Vrachatis, Siasos, Giotaki et al., Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019, JAMA Network Open,
doi:10.1001/jamanetworkopen.2020.13136Fadel, Morrison, Vahia, Smith, Chaudhry et al., Henry Ford COVID-19 Management Task Force
Gong, Ou, Qiu, Jie, Chen et al., A tool for early prediction of severe coronavirus disease 2019 (COVID-19): a multicenter study using the risk nomogram in Wuhan and Guangdong, China Clin Infect Dis,
doi:10.1093/cid/ciaa443Grasselli, Zangrillo, Zanella, Antonelli, Cabrini et al., Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy, JAMA,
doi:10.1001/jama.2020.5394Guaraldi, Meschiari, Cozzi-Lepri, Milic, Tonelli et al., Tocilizumab in patients with severe COVID-19: a retrospective cohort study. The lancet, Rheumatology,
doi:10.1016/S2665-9913(20)30173-9Huang, Pranata, Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis, J Intensive Care,
doi:10.1186/s40560-020-00453-4Kewan, Covut, Mj, Rose, Gopalakrishna et al., Tocilizumab for treatment of patients with severe COVID-19: a retrospective cohort study, E Clin Med,
doi:10.1016/j.eclinm.2020.100418Klopfenstein, Zayet, Lohse, Balblanc, Badie et al., Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients, Médecine et Maladies Infectieuses,
doi:10.1016/j.medmal.2020.05.001Li, Xu, Yu, Wang, Tao et al., Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan, J Aller Clin Immunol,
doi:10.1016/j.jaci.2020.04.006Mohfw, Gov, None
Ranieri, Rubenfeld, Thompson, Ferguson, Caldwell, Acute respiratory distress syndrome: the Berlin definition, JAMA,
doi:10.1001/jama.2012.5669Richardson, Hirsch, Narasimhan, Crawford, Mcginn et al., Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area, JAMA,
doi:10.1001/jama.2020.6775Ruan, Yang, Wang, Jiang, Song, Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China, Intensive Care Med,
doi:10.1007/s00134-020-05991-xSiddiqi, Mehra, COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal, J Heart Lung Transplantat,
doi:10.1016/j.healun.2020.03.012Tufan, Güler, Matucci-Cerinic, COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs, Turk J Med Sci,
doi:10.3906/sag-2004-168Wang, He, Yu, Hu, Bao et al., Coronavirus disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up, J Infect,
doi:10.1016/j.jinf.2020.03.01Wu, Chen, Cai, Xia, Zhou et al., Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China, JAMA Int Med,
doi:10.1001/jamainternmed.2020.0994Yang, Yu, Xu, Shu, Xia et al., Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study, Lancet Respirat Med,
doi:10.1016/S2213-2600(20)30079-5Zhang, Qin, Li, Wang, Zhao et al., A novel scoring system for prediction of disease severity in COVID-19, Front Cell Infect Microbiol,
doi:10.3389/fcimb.2020.00318Zhou, Yu, Du, Fan, Liu et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet,
doi:10.1016/S0140-6736(20)30566-3
